Browsing: biosimilar
In June, the Supreme Court overturned the decades-old Chevron doctrine that empowered a federal agency’s “reasonable interpretation of ambiguous federal…
Beginning in 2023, five years after their European counterparts, patients in the United States prescribed the autoimmune disease treatment Humira…
Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making inroads in…
It’s hard to find bipartisan consensus among lawmakers in Congress these days. But there’s widespread agreement on calls for pharmaceutical…
According to a federal government Medicare Payment Advisory Commission report published last month, more than 40% of Medicare beneficiaries still…